Ekso Bionics Holdings, Inc. (EKSO) DCF Valuation
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Ekso Bionics Holdings, Inc. (EKSO) Bundle
Explore the financial future of Ekso Bionics Holdings, Inc. (EKSO) with our user-friendly DCF Calculator! Enter your assumptions for growth, margins, and expenses to calculate the intrinsic value of Ekso Bionics Holdings, Inc. (EKSO) and enhance your investment strategy.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 13.9 | 8.9 | 11.2 | 12.9 | 18.3 | 20.4 | 22.8 | 25.5 | 28.5 | 31.8 |
| Revenue Growth, % | 0 | -36.18 | 26.62 | 14.81 | 41.57 | 11.7 | 11.7 | 11.7 | 11.7 | 11.7 |
| EBITDA | -11.1 | -15.1 | -9.1 | -14.0 | -13.2 | -17.7 | -19.7 | -22.0 | -24.6 | -27.5 |
| EBITDA, % | -79.46 | -169.62 | -80.83 | -108.71 | -72.2 | -86.5 | -86.5 | -86.5 | -86.5 | -86.5 |
| Depreciation | .7 | .6 | .6 | .9 | 1.7 | 1.4 | 1.5 | 1.7 | 1.9 | 2.1 |
| Depreciation, % | 4.96 | 6.98 | 4.99 | 6.87 | 9.29 | 6.62 | 6.62 | 6.62 | 6.62 | 6.62 |
| EBIT | -11.7 | -15.7 | -9.7 | -14.9 | -14.9 | -18.4 | -20.6 | -23.0 | -25.7 | -28.7 |
| EBIT, % | -84.41 | -176.6 | -85.82 | -115.58 | -81.49 | -90.34 | -90.34 | -90.34 | -90.34 | -90.34 |
| Total Cash | 10.9 | 12.9 | 40.4 | 20.5 | 8.6 | 17.4 | 19.4 | 21.7 | 24.2 | 27.0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 5.2 | 3.4 | 4.7 | 4.6 | 5.6 | 7.5 | 8.4 | 9.4 | 10.5 | 11.7 |
| Account Receivables, % | 37.42 | 38.16 | 41.45 | 35.82 | 30.88 | 36.75 | 36.75 | 36.75 | 36.75 | 36.75 |
| Inventories | 2.5 | 2.0 | 2.2 | 5.2 | 5.1 | 5.2 | 5.8 | 6.5 | 7.3 | 8.1 |
| Inventories, % | 17.88 | 22.27 | 19.94 | 40.17 | 27.63 | 25.58 | 25.58 | 25.58 | 25.58 | 25.58 |
| Accounts Payable | 1.9 | 1.5 | 3.1 | 3.2 | 1.8 | 3.8 | 4.2 | 4.7 | 5.3 | 5.9 |
| Accounts Payable, % | 13.67 | 16.9 | 27.63 | 24.4 | 10.1 | 18.54 | 18.54 | 18.54 | 18.54 | 18.54 |
| Capital Expenditure | -.1 | .0 | -.1 | -.2 | -.2 | -.1 | -.2 | -.2 | -.2 | -.2 |
| Capital Expenditure, % | -0.43113 | 0 | -0.52463 | -1.5 | -0.85891 | -0.66343 | -0.66343 | -0.66343 | -0.66343 | -0.66343 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -11.3 | -16.8 | -8.3 | -14.5 | -14.9 | -17.7 | -19.8 | -22.1 | -24.7 | -27.5 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -16.5 | -14.3 | -7.8 | -16.6 | -15.5 | -16.6 | -19.5 | -21.7 | -24.3 | -27.1 |
| WACC, % | 8.26 | 8.33 | 8.06 | 8.27 | 8.33 | 8.25 | 8.25 | 8.25 | 8.25 | 8.25 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -85.0 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -28 | |||||||||
| Terminal Value | -442 | |||||||||
| Present Terminal Value | -298 | |||||||||
| Enterprise Value | -382 | |||||||||
| Net Debt | -1 | |||||||||
| Equity Value | -381 | |||||||||
| Diluted Shares Outstanding, MM | 14 | |||||||||
| Equity Value Per Share | -27.48 |
What You Will Get
- Real Ekso Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for Ekso Bionics Holdings, Inc. (EKSO).
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates to fit your analysis.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Ekso Bionics' fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections specific to Ekso Bionics Holdings, Inc. (EKSO).
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility in your financial assessments.
Key Features
- Innovative Exoskeleton Technology: Cutting-edge designs aimed at enhancing mobility and rehabilitation.
- Real-Time Data Analytics: Integrated analytics for monitoring performance and user engagement.
- Customizable User Interfaces: Tailor settings and preferences to individual user needs.
- Comprehensive Training Programs: Structured training modules for users and healthcare professionals.
- Robust Support and Resources: Access to a library of tutorials, manuals, and customer support.
How It Works
- Step 1: Download the prebuilt Excel template featuring Ekso Bionics Holdings, Inc. (EKSO) data.
- Step 2: Navigate through the pre-filled sheets to familiarize yourself with the essential metrics.
- Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly see the recalibrated results, including the intrinsic value of Ekso Bionics Holdings, Inc. (EKSO).
- Step 5: Make well-informed investment decisions or create reports based on the outputs.
Why Choose This Calculator for Ekso Bionics Holdings, Inc. (EKSO)?
- Accurate Data: Utilize real Ekso Bionics financials for dependable valuation outcomes.
- Customizable: Tailor essential parameters such as growth rates, WACC, and tax rates to fit your forecasts.
- Time-Saving: Pre-configured calculations save you the hassle of starting from the ground up.
- Professional-Grade Tool: Crafted for investors, analysts, and consultants in the field.
- User-Friendly: Easy-to-navigate interface and clear instructions make it accessible for all users.
Who Should Use This Product?
- Healthcare Professionals: Understand the application of exoskeleton technology in rehabilitation settings.
- Researchers: Integrate advanced robotics concepts into studies on mobility and assistive devices.
- Investors: Evaluate your investment strategies and analyze the market potential of Ekso Bionics Holdings, Inc. (EKSO).
- Engineers: Enhance your projects with innovative designs and customizable solutions in bionic technology.
- Physical Therapists: Discover how exoskeletons can improve patient outcomes and streamline therapy sessions.
What the EKSO Template Contains
- Comprehensive DCF Model: Editable template featuring detailed valuation calculations for EKSO.
- Real-World Data: Ekso Bionics' historical and projected financials preloaded for in-depth analysis.
- Customizable Parameters: Modify WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for enhanced insights into EKSO's performance.
- Key Ratios: Integrated analysis for profitability, efficiency, and leverage specific to EKSO.
- Dashboard with Visual Outputs: Engaging charts and tables for clear, actionable results.